Gene therapy is a fast-moving area. To keep up with the rapid development, CombiGene is attending all major scientific congresses. At the end of November, CombiGene’s Director in Preclinical Development Annika Ericsson attended the 4th Annual Gene Therapy Analytical Development in Boston, MA.
“The congress in Boston is a prime example of what a vibrant community the gene therapy space really is. The congress gathered more than 300 analytical experts from academia and industry to discuss development of analytical tools with the objective to enhance safety, quality, and effect of gene therapy vectors. Advances are done almost daily, and it is very important for CombiGene to keep up with the latest developments so that we know how current analytical methods are being improved and what requirements must be met in order to bring a project to clinical trial. Leading pharmaceutical companies such as AstraZeneca, Sanofi, Novartis, Bluebird Bio, Biogen, Johnson & Johnson all attended the congress, and there were many opportunities to meet with these leading industry experts through workshops, interactive panel discussions, and Q&A sessions,” says Annika Ericsson.